Key Takeaways
- • CVC Capital Partners names Todd Sisitsky as co-CEO effective 2028, ending a long-planned succession process following the departure of current CEO Rob Lucas. Sisitsky will share the role with Peter Rutland, CVC's president and head of financial services.
- • Sisitsky joins CVC from TPG, where he has served as president since 2021 and will continue to play an active role in the firm's healthcare investment activities during his transition.
- • The appointment represents a dual-leadership structure designed to leverage Sisitsky's healthcare sector expertise alongside Rutland's financial services leadership, signaling CVC's strategic focus on both verticals.
- • Sisitsky brings substantial board experience, currently serving on the public boards of IQVIA Holdings and Allogene Therapeutics, and has been with TPG since 2003, demonstrating deep alternative asset management credentials.
Summary
CVC Capital Partners has announced the hiring of Todd Sisitsky as co-chief executive officer, effective 2028, marking the conclusion of a succession planning process initiated by the departure of current CEO Rob Lucas. Sisitsky will assume the co-CEO role alongside Peter Rutland, CVC's president and head of the firm's financial services division, creating a dual-leadership model that balances sector expertise.
Sisitsky currently serves as president of TPG, a position he has held since 2021. Prior to this role, he joined TPG in 2003 and has built a career focused on healthcare services and pharmaceutical/medical device sector investments. The transition preserves his active involvement in TPG's healthcare investment portfolio during his move to CVC, ensuring continuity in this specialized practice area. Beyond his TPG responsibilities, Sisitsky maintains board directorships at publicly traded IQVIA Holdings and Allogene Therapeutics, underscoring his standing within the healthcare and life sciences investment community.
The co-CEO structure reflects CVC's strategic positioning across two core competency areas: Rutland's established leadership in financial services and Sisitsky's deep expertise in healthcare sector investments. This appointment signals CVC's confidence in Sisitsky's ability to drive growth and strategy across the firm's portfolio while leveraging his two decades of experience in alternative asset management. The 2028 effective date provides an orderly transition period and continuity for ongoing portfolio management and client relationships.
Sisitsky currently serves as president of TPG, a position he has held since 2021. Prior to this role, he joined TPG in 2003 and has built a career focused on healthcare services and pharmaceutical/medical device sector investments. The transition preserves his active involvement in TPG's healthcare investment portfolio during his move to CVC, ensuring continuity in this specialized practice area. Beyond his TPG responsibilities, Sisitsky maintains board directorships at publicly traded IQVIA Holdings and Allogene Therapeutics, underscoring his standing within the healthcare and life sciences investment community.
The co-CEO structure reflects CVC's strategic positioning across two core competency areas: Rutland's established leadership in financial services and Sisitsky's deep expertise in healthcare sector investments. This appointment signals CVC's confidence in Sisitsky's ability to drive growth and strategy across the firm's portfolio while leveraging his two decades of experience in alternative asset management. The 2028 effective date provides an orderly transition period and continuity for ongoing portfolio management and client relationships.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.